Cargando…

Брадикинин и ангиотензин-превращающий фермент в крови больных с диабетической ретинопатией и прогноз развития диабетического макулярного отека (пилотное исследование)

BACKGROUND. Diabetic macular edema (DME) is a microvascular complication of diabetic retinopathy. One of the key roles in the pathogenesis of DME may belong to the components of rennin-angiotensin and kallikrein-kinin systems: bradykinin (Bk) and angiotensin-converting enzyme (ACE).PURPOSE. To deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Нероев, В. В., Чеснокова, Н. Б., Кост, О. А., Охоцимская, Т. Д., Павленко, Т. А., Безнос, О. В., Биневский, П. В., Лисовская, О. А.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrinology Research Centre 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753801/
https://www.ncbi.nlm.nih.gov/pubmed/34533010
http://dx.doi.org/10.14341/probl12762
_version_ 1784851044276109312
author Нероев, В. В.
Чеснокова, Н. Б.
Кост, О. А.
Охоцимская, Т. Д.
Павленко, Т. А.
Безнос, О. В.
Биневский, П. В.
Лисовская, О. А.
author_facet Нероев, В. В.
Чеснокова, Н. Б.
Кост, О. А.
Охоцимская, Т. Д.
Павленко, Т. А.
Безнос, О. В.
Биневский, П. В.
Лисовская, О. А.
author_sort Нероев, В. В.
collection PubMed
description BACKGROUND. Diabetic macular edema (DME) is a microvascular complication of diabetic retinopathy. One of the key roles in the pathogenesis of DME may belong to the components of rennin-angiotensin and kallikrein-kinin systems: bradykinin (Bk) and angiotensin-converting enzyme (ACE).PURPOSE. To determine the Bk and ACE concentration and ACE activity in serum of patients with proliferative diabetic retinopathy (PDR) and to estimate the significance of these parameters for the early diagnostic and prognosis of DMO.MATERIALS AND METHODS. Serum was collected from the 2 groups of patients with II type diabetes. Group I (n=9) had DME, group II (n=27) had PDR without DME. Control group (n=14) consisted of adult volonteers without diabetes and ophthalmic diseases. Concentration of Bk and ACE was measured using ELISA kits, ACE activity was determined enzymatically with specific fluorogenic substrate.RESULTS. Concentration of Bk in serum of patients without DME did not differ from one in controls (12,00 (9,70; 12,40) pg/ml) while all patients with DME had Bk level of 14,69 (13,68; 16,78) pg/ml that was significantly higher (p<0,01). In patients without DME ACE concentration (88,60 (77,30; 97,45) ng/ml) and ACE activity (6,8 (5,1;7,1) nmol/min·ml) were higher than normal (p<0,01) while in the case of DME concentration of ACE increased (77,36 (70,24; 86,29 ng/ml, p<0,01) and activity remained normal. The Bk/ACE concentrations ratio decreased in patients without DME and increased in those having DME.CONCLUSION. Patients with DME have increased Bk concentration along with nearly normal ACE concentration that indicate predominance of Bk synthesis over its degradation that may lead to the DME development. The Bk/ACE ratio decrease in patients with uncomplicated PDR and increase significantly in ones with DME. It means that determination of Bk in serum of patients with PDR may be used for the prediction of DME development. The Bk/ACE concentrations ratio may be even more informative.
format Online
Article
Text
id pubmed-9753801
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Endocrinology Research Centre
record_format MEDLINE/PubMed
spelling pubmed-97538012022-12-16 Брадикинин и ангиотензин-превращающий фермент в крови больных с диабетической ретинопатией и прогноз развития диабетического макулярного отека (пилотное исследование) Нероев, В. В. Чеснокова, Н. Б. Кост, О. А. Охоцимская, Т. Д. Павленко, Т. А. Безнос, О. В. Биневский, П. В. Лисовская, О. А. Probl Endokrinol (Mosk) Research Article BACKGROUND. Diabetic macular edema (DME) is a microvascular complication of diabetic retinopathy. One of the key roles in the pathogenesis of DME may belong to the components of rennin-angiotensin and kallikrein-kinin systems: bradykinin (Bk) and angiotensin-converting enzyme (ACE).PURPOSE. To determine the Bk and ACE concentration and ACE activity in serum of patients with proliferative diabetic retinopathy (PDR) and to estimate the significance of these parameters for the early diagnostic and prognosis of DMO.MATERIALS AND METHODS. Serum was collected from the 2 groups of patients with II type diabetes. Group I (n=9) had DME, group II (n=27) had PDR without DME. Control group (n=14) consisted of adult volonteers without diabetes and ophthalmic diseases. Concentration of Bk and ACE was measured using ELISA kits, ACE activity was determined enzymatically with specific fluorogenic substrate.RESULTS. Concentration of Bk in serum of patients without DME did not differ from one in controls (12,00 (9,70; 12,40) pg/ml) while all patients with DME had Bk level of 14,69 (13,68; 16,78) pg/ml that was significantly higher (p<0,01). In patients without DME ACE concentration (88,60 (77,30; 97,45) ng/ml) and ACE activity (6,8 (5,1;7,1) nmol/min·ml) were higher than normal (p<0,01) while in the case of DME concentration of ACE increased (77,36 (70,24; 86,29 ng/ml, p<0,01) and activity remained normal. The Bk/ACE concentrations ratio decreased in patients without DME and increased in those having DME.CONCLUSION. Patients with DME have increased Bk concentration along with nearly normal ACE concentration that indicate predominance of Bk synthesis over its degradation that may lead to the DME development. The Bk/ACE ratio decrease in patients with uncomplicated PDR and increase significantly in ones with DME. It means that determination of Bk in serum of patients with PDR may be used for the prediction of DME development. The Bk/ACE concentrations ratio may be even more informative. Endocrinology Research Centre 2021-08-19 /pmc/articles/PMC9753801/ /pubmed/34533010 http://dx.doi.org/10.14341/probl12762 Text en Copyright © Endocrinology Research Centre, 2021 https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 License.
spellingShingle Research Article
Нероев, В. В.
Чеснокова, Н. Б.
Кост, О. А.
Охоцимская, Т. Д.
Павленко, Т. А.
Безнос, О. В.
Биневский, П. В.
Лисовская, О. А.
Брадикинин и ангиотензин-превращающий фермент в крови больных с диабетической ретинопатией и прогноз развития диабетического макулярного отека (пилотное исследование)
title Брадикинин и ангиотензин-превращающий фермент в крови больных с диабетической ретинопатией и прогноз развития диабетического макулярного отека (пилотное исследование)
title_full Брадикинин и ангиотензин-превращающий фермент в крови больных с диабетической ретинопатией и прогноз развития диабетического макулярного отека (пилотное исследование)
title_fullStr Брадикинин и ангиотензин-превращающий фермент в крови больных с диабетической ретинопатией и прогноз развития диабетического макулярного отека (пилотное исследование)
title_full_unstemmed Брадикинин и ангиотензин-превращающий фермент в крови больных с диабетической ретинопатией и прогноз развития диабетического макулярного отека (пилотное исследование)
title_short Брадикинин и ангиотензин-превращающий фермент в крови больных с диабетической ретинопатией и прогноз развития диабетического макулярного отека (пилотное исследование)
title_sort брадикинин и ангиотензин-превращающий фермент в крови больных с диабетической ретинопатией и прогноз развития диабетического макулярного отека (пилотное исследование)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753801/
https://www.ncbi.nlm.nih.gov/pubmed/34533010
http://dx.doi.org/10.14341/probl12762
work_keys_str_mv AT neroevvv bradikininiangiotenzinprevraŝaûŝijfermentvkrovibolʹnyhsdiabetičeskojretinopatiejiprognozrazvitiâdiabetičeskogomakulârnogootekapilotnoeissledovanie
AT česnokovanb bradikininiangiotenzinprevraŝaûŝijfermentvkrovibolʹnyhsdiabetičeskojretinopatiejiprognozrazvitiâdiabetičeskogomakulârnogootekapilotnoeissledovanie
AT kostoa bradikininiangiotenzinprevraŝaûŝijfermentvkrovibolʹnyhsdiabetičeskojretinopatiejiprognozrazvitiâdiabetičeskogomakulârnogootekapilotnoeissledovanie
AT ohocimskaâtd bradikininiangiotenzinprevraŝaûŝijfermentvkrovibolʹnyhsdiabetičeskojretinopatiejiprognozrazvitiâdiabetičeskogomakulârnogootekapilotnoeissledovanie
AT pavlenkota bradikininiangiotenzinprevraŝaûŝijfermentvkrovibolʹnyhsdiabetičeskojretinopatiejiprognozrazvitiâdiabetičeskogomakulârnogootekapilotnoeissledovanie
AT beznosov bradikininiangiotenzinprevraŝaûŝijfermentvkrovibolʹnyhsdiabetičeskojretinopatiejiprognozrazvitiâdiabetičeskogomakulârnogootekapilotnoeissledovanie
AT binevskijpv bradikininiangiotenzinprevraŝaûŝijfermentvkrovibolʹnyhsdiabetičeskojretinopatiejiprognozrazvitiâdiabetičeskogomakulârnogootekapilotnoeissledovanie
AT lisovskaâoa bradikininiangiotenzinprevraŝaûŝijfermentvkrovibolʹnyhsdiabetičeskojretinopatiejiprognozrazvitiâdiabetičeskogomakulârnogootekapilotnoeissledovanie